Menu Search
Equities

PCI Biotech Holding ASA

4QG:FRA

PCI Biotech Holding ASA

Actions
  • Price (EUR)0.1234
  • Today's Change-0.008 / -6.23%
  • Shares traded5.00k
  • 1 Year change-31.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.

  • Revenue in NOK (TTM)6.00m
  • Net income in NOK-16.00m
  • Incorporated2007
  • Employees7.00
  • Location
    PCI Biotech Holding ASAUllernchauseen 64OSLO 0379NorwayNOR
  • Phone+47 67115400
  • Fax+47 67115401
  • Websitehttps://www.pcibiotech.no/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.